Professor Mathias Rummel from Giessen, Germany, talks to ecancer.TV about the current management of indolent lymphoma with chemotherapy and rituximab, and rituximab maintenance, highlighting the limitations of this regimen. He goes on to outline potential new agents for indolent lymphoma, for example, promising early data with obinutuzumab (GA11),GS-1101 and ibrutinib used in combination with existing therapy, as well as some promise shown as single agent therapy. He also discusses other potential targets in indolent lymphoma, and summarises data on the use of interferon.
Professor Rummel comments on the toxicities with these newer agents, and the importance of balancing frequency and duration of therapy with toxicity. He also emphasises the importance of focusing on quality of life in the management of this condition, commenting on the BRIGHT study.